Methiopropamine (MPA; 1-(thiophen-2-yl)-2-methylaminopropane) is a synthetic stimulant of the thiophene chemical class — a structural analog of methamphetamine in which the phenyl ring is replaced by a thiophene ring (a five-membered aromatic ring containing one sulfur atom). This bioisosteric substitution — replacing benzene with thiophene while retaining the overall molecular framework — represents a classic medicinal chemistry approach to modulating pharmacological properties.
MPA acts as a selective norepinephrine-dopamine releasing agent with approximately one-third the norepinephrine reuptake inhibitor potency and one-seventh the dopamine reuptake inhibitor potency of methamphetamine, making it substantially less potent overall. Community experience describes its effects as lighter and shorter-acting than methamphetamine — a mild to moderate stimulant producing wakefulness, motivation, and modest mood elevation without the intense euphoria of methamphetamine. Duration is typically 3–5 hours, shorter than methamphetamine analogs.
MPA achieved a period of mainstream visibility in the UK "legal high" market around 2009–2013, marketed in products as a "legal methamphetamine alternative" before being explicitly scheduled. It was one of the earlier research chemical stimulants to develop substantial community harm reduction documentation in UK-centric drug forums. Despite its lower potency, MPA is not without risk: it carries standard stimulant cardiovascular and dependence risks, and its thiophene ring raises theoretical questions about reactive metabolite formation — a concern with thiophene-containing drugs generally.
Safety at a Glance
High Risk- Lower Potency Does Not Mean Safer
- Based on community experience:
- Toxicity: Acute Toxicity No formal human toxicological studies exist for MPA. Based on its mechanism (selective NDRA) and commu...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Atropa belladonna, Datura, MDMA (+3 more)
- Overdose risk: Stimulant overdose from Methiopropamine is a medical emergency primarily involving cardiovascular...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
insufflated
oral
Duration
insufflated
Total: 2 hrs – 4 hrsoral
Total: 6 hrs – 10 hrsHow It Feels
Methiopropamine arrives with the quiet competence of a functional stimulant that knows its place. Within twenty to forty minutes of oral ingestion, or somewhat faster when insufflated, a calm alertness begins to establish itself. Fatigue recedes. Focus sharpens. There is a mild increase in motivation and a subtle but genuine sense that tasks are more approachable than they were half an hour ago. The onset is unremarkable in its smoothness, offering none of the dramatic rush or euphoria that characterizes recreational stimulants.
At its functional peak, typically reached within an hour, methiopropamine produces a state of enhanced concentration and sustained attention. The mind locks onto tasks with a pleasant efficiency. Distractibility decreases, and there is an ability to work through material that would ordinarily provoke boredom or avoidance. The mood lifts slightly, though the elevation is subtle enough that it might be attributed to the satisfaction of getting things done rather than to any direct pharmacological warmth. Social interactions feel slightly easier, and there is a mild increase in verbal fluency, but the compound is not social in the way that more serotonergic stimulants are. This is a tool for work, not for parties.
Physical effects are mild and manageable. Heart rate increases modestly. Appetite is suppressed. There may be a slight dryness of the mouth and a barely perceptible tremor in the hands. The overall physical load is light, making methiopropamine one of the more physically comfortable stimulants in its class. There is none of the aggressive vasoconstriction, jaw clenching, or temperature dysregulation that accompanies more potent compounds. The body feels alert but not strained.
The effects last three to six hours, tapering gradually and without drama. The comedown is gentle, characterized by a slow return of fatigue and normal distractibility rather than any acute crash or emotional deficit. Sleep is achievable within a few hours of the effects wearing off. The following morning feels normal. The overall experience is defined by its unremarkable competence, a substance that does what a functional stimulant should do and nothing more. It lacks the glamour, the danger, and the recreational potential of more potent compounds, and for its intended purpose, this absence is a feature rather than a flaw.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(8)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Spontaneous tactile sensations— Unprompted physical sensations that arise without external touch or stimulus, manifesting as tinglin...
Cognitive & Perceptual Effects
Cognitive(14)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Thought organization— Enhanced ability to structure, categorize, and systematize thoughts and ideas, common with low-dose ...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Mechanism of Action
MPA functions as a selective norepinephrine-dopamine releasing agent (NDRA) — releasing norepinephrine and dopamine from their respective presynaptic stores via transporter reversal. It does not act significantly as a serotonin releasing agent, making it a non-entactogenic stimulant without MDMA-like properties.
Potency relative to methamphetamine is approximately:
- NET inhibition: ~1/3 the potency of methamphetamine
- DAT inhibition: ~1/7 the potency of methamphetamine
This lower potency profile means MPA requires substantially higher doses than methamphetamine to produce equivalent stimulation — a factor that can inadvertently lead to higher absolute doses and potential for unexpected toxicity.
Receptor Profile
- NET — Primary releasing agent target; norepinephrine-dominant activity produces wakefulness and cardiovascular effects
- DAT — Secondary; dopamine release drives mild euphoria and motivation
- SERT — Minimal activity; not a significant serotonin releasing agent
Pharmacokinetics
Based on community experience data:
- Onset: 15–30 minutes insufflated; 30–60 minutes oral
- Peak: 1–2 hours
- Duration: 3–5 hours
- Shorter duration than methamphetamine, partly attributable to the thiophene ring's metabolic properties
Thiophene Bioisosterism
Thiophene is a classical bioisostere for benzene in medicinal chemistry — the two rings have similar electronic properties and spatial dimensions. However, thiophene-containing drugs occasionally produce unique toxic metabolites via CYP-mediated ring oxidation (thiophene S-oxide, epoxide metabolites), which has been associated with hepatotoxicity and idiosyncratic toxicity in some drug classes.
Detection Methods
Standard Drug Panel Inclusion
Methiopropamine (MPA) is a thiophene analogue of methamphetamine that is generally not detected on standard 5-panel immunoassay drug screens. The replacement of the phenyl ring with a thiophene ring reduces cross-reactivity with amphetamine/methamphetamine immunoassays, though some assays may show weak cross-reactivity at high concentrations.
Urine Detection
Methiopropamine can be detected in urine for approximately 2 to 4 days after use. Metabolic pathways include N-demethylation and thiophene ring oxidation. Standard immunoassay screens are unreliable for detecting MPA. Targeted LC-MS/MS analysis with MPA reference standards is required.
Blood and Saliva Detection
Blood detection windows are approximately 12 to 36 hours. Oral fluid testing can detect parent compound for a similar duration. Neither modality routinely includes thiophene-substituted amphetamines.
Hair Follicle Detection
Hair follicle analysis for MPA requires custom analytical methods. Standard hair testing panels do not include thiophene amphetamine analogues. Detection is possible for up to 90 days with appropriate LC-MS/MS methods.
Confirmatory Testing
LC-MS/MS and GC-MS can identify MPA and distinguish it from methamphetamine based on molecular weight and the thiophene-specific fragmentation pattern. The sulfur atom in the thiophene ring provides a distinctive mass spectrometric signature.
Reagent Testing
Marquis reagent typically produces a faint yellow to orange color with MPA, less intense than the reaction seen with methamphetamine. Simon's reagent is positive (secondary amine), consistent with the N-methyl group. Mecke and Mandelin reagents show minimal reactions. The weaker Marquis response compared to methamphetamine is a useful field-level distinction.
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDMA | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
Synthesis and Early History
Methiopropamine was first synthesized in 1942 as part of early exploration of thiophene bioisosteres — the demonstration that substituting thiophene for benzene in biological molecules could produce compounds with retained biological activity. It appeared in pharmacological literature as a reference compound without significant pharmaceutical development.
UK Legal High Era (2009–2013)
MPA achieved widespread visibility in the UK research chemical and "legal high" market beginning around 2009. It was marketed in products including "NRG-1" (Next Generation Radiance-1), "Ivory Wave," and other branded "legal high" preparations as a notional legal alternative to methamphetamine. The UK Forensic Science Service and Advisory Council on the Misuse of Drugs documented its prevalence and associated adverse events.
Scheduling
MPA was specifically added to the Misuse of Drugs Act in the UK in 2013. It has been controlled in several European jurisdictions and the US. Its scheduling reflected both the documented adverse event profile from the legal high era and the broader pattern of UK legislative response to novel psychoactive substances.
Legacy
MPA represents an early and well-documented example of a "bioisosteric" research chemical stimulant that achieved mass-market exposure via the legal high industry before formal research documentation occurred. The UK experience with MPA-containing products influenced subsequent approaches to novel psychoactive substance regulation and the eventual blanket legislation of the Psychoactive Substances Act 2016.
Harm Reduction
Lower Potency Does Not Mean Safer
MPA's lower potency relative to methamphetamine is not equivalent to safety. Users who escalate doses in pursuit of methamphetamine-like effects can reach absolute doses that produce significant cardiovascular and psychological risks.
Dose Reference
Based on community experience:
- Threshold: ~50 mg oral/insufflated
- Common: 75–150 mg oral
- Strong: 150–250 mg oral
The lower potency relative to methamphetamine creates large dose numbers that can obscure risk escalation.
Insufflation Risk
MPA is commonly used by insufflation despite nasal irritation. Oral administration is preferable to reduce mucosal irritation and provide more controlled absorption.
Thiophene Concern — Monitor Liver
While theoretical, the reactive metabolite concern from the thiophene ring is sufficient to recommend monitoring for hepatotoxicity symptoms with regular use (jaundice, right upper quadrant pain, dark urine).
Do Not Combine with MAOIs
Absolute contraindication: risk of hypertensive crisis from norepinephrine releasing activity combined with MAOI-mediated reuptake inhibition.
Legal High Context Caution
Products historically sold as containing MPA may be adulterated or misrepresented. If acquiring from these contexts, analytical verification is important.
Toxicity & Safety
Acute Toxicity
No formal human toxicological studies exist for MPA. Based on its mechanism (selective NDRA) and community UK experience:
- Cardiovascular stimulation (tachycardia, hypertension) is the primary acute risk
- The norepinephrine-dominant profile may produce more pronounced cardiovascular effects relative to euphoria than dopamine-dominant compounds
Thiophene Reactive Metabolite Concern
A theoretical but pharmacologically relevant concern: some thiophene-containing drugs (methapyrilene, tienilic acid) are associated with hepatotoxicity via CYP450-mediated formation of reactive thiophene metabolites (S-oxides, epoxides). Whether MPA produces such metabolites and at what doses this is relevant is unknown. This is not an established clinical finding for MPA specifically but represents a mechanistic concern for chronic or heavy use.
Cardiovascular Risk
Given its norepinephrine-dominant releasing agent activity, MPA may produce more cardiovascular activation (tachycardia, hypertension) relative to its subjective euphoria than dopaminergic stimulants. Users seeking more intense effects may overdose relative to what the euphoric component indicates.
UK Adverse Events
During the UK "legal high" era (2009–2013), MPA was associated with adverse events including cardiovascular presentations and psychiatric crises — though the contribution of MPA vs. adulterants in legal high products makes attribution complex. The UK Forensic Science Service documented MPA in "NRG-1" and similar products.
Dependence
As a dopamine/norepinephrine releasing agent, MPA carries stimulant dependence potential, though lower potency than methamphetamine likely reduces compulsive use drive.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Stimulant overdose from Methiopropamine is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Austria: Since June 26, 2019, Methiopropamine is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
China: Methiopropamine is a controlled substance.
Finland: Methiopropamine is illegal in Finland.
France: Methiopropamine is scheduled as a "stupéfiant", i.e. a recognized drug of abuse. It is illegal to possess, buy, sell or manufacture.
Germany: Methiopropamine is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of July 17, 2013. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Switzerland: Methiopropamine is a controlled substance specifically named under Verzeichnis D.
United Kingdom: Methiopropamine is a Class B drug.
United States: Methiopropamine is not scheduled at the federal level in the United States, but it could be considered an analogue of methamphetamine in which case purchase, sale, or possession could be prosecuted under the Federal Analogue Act. Methiopropamine's structure differs from methamphetamine's structure significantly more than previous successful prosecutions under the same law.
Florida: Methiopropamine is a Schedule I controlled substance in the state of Florida, making it illegal to buy, sell, or possess in Florida.
Responsible use
Methamphetamine
Stimulant
Methiopropamine (Wikipedia)
Methiopropamine (Erowid Vault)
Methiopropamine (Isomer Design)
Methiopropamine (MyCrew)
Tips (4)
Do not combine Methiopropamine with MAOIs or other serotonergic drugs. Many stimulants have serotonergic activity, and combinations can cause serotonin syndrome or hypertensive crisis, both medical emergencies.
Have a landing plan for the Methiopropamine comedown. Prepare food, melatonin or magnesium, and a comfortable environment in advance. Avoid using depressants to manage the comedown as this creates polydrug dependency patterns.
Start low with Methiopropamine and wait for full onset before redosing. Stimulant redosing extends duration and side effects more than it extends euphoria, while adding cardiovascular strain. Set a firm limit before you start.
Test Methiopropamine with appropriate reagent kits and fentanyl test strips. Stimulant supplies have increasingly been found contaminated with fentanyl, which has caused a surge in overdose deaths among stimulant users.
See Also
References (4)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- PubChem: Methiopropamine
PubChem compound page for Methiopropamine (CID: 436156)
pubchem - Methiopropamine - TripSit Factsheet
TripSit factsheet for Methiopropamine
tripsit - Methiopropamine - Wikipedia
Wikipedia article on Methiopropamine
wikipedia